<DOC>
	<DOCNO>NCT02804100</DOCNO>
	<brief_summary>A multi-centre observational , non-interventional study dynamically monitor change circulate tumor DNA ( ctDNA ) late stage NSCLC patient Gefitinib treatment .</brief_summary>
	<brief_title>Dynamic Changes Circulating Tumor DNA Late Stage NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bronchial Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Bronchogenic</mesh_term>
	<criteria>Provision inform consent Histologically confirm stage IIIB/IV NSCLC . Activating EGFR mutation ( G719A/C/S ; Exon 19 insertion/deletion ; L858R ; L861Q ) Able comply require protocol followedup procedure , able receive oral medication Histologically confirm small cell lung cancer metastatic tumor Patient receive prior chemotherapy EGFRTKIs treatment Patients harbor Exon20 T790M mutation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Circulating Tumor DNA</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Plasma DNA</keyword>
</DOC>